Aminoglycoside Use and Intensive Care Unit-acquired Weakness: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Mar 20

PMID 32191708

Citations 5

Authors

Tao Yang

Zhi-Qiang Li

Hong-Liang Li

Jian-Xin Zhou

Guang-Qiang Chen

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between aminoglycoside use and intensive care unit (ICU)-acquired weakness remains controversial. In the present study, we performed a systematic review and meta-analysis to examine the relationship between aminoglycoside use and ICU-acquired weakness in critically ill patients.

Methods: The PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials and Cumulative Index of Nursing and Allied Health Literature databases were searched from the earliest available date to July 10, 2019. Randomized controlled trials and prospective cohort studies examining the relationship between aminoglycosides and ICU-acquired weakness in adult ICU patients were included. Two authors independently screened titles/abstracts, reviewed full text and extracted data from the included studies. We performed the Meta-analysis using Stata version 15.0 and used the DerSimonian-Laird random effects model for data analyses. Heterogeneity was evaluated using the χ2 statistic and I2 statistic. Publication bias was evaluated with funnel plots qualitatively, the Begg's test and Egger's test quantitatively.

Results: Ten prospective cohort studies were included and analysed in this review. The overall effect sizes of the studies revealed a statistically significant relationship between aminoglycoside use and ICU-acquired weakness (OR, 2.06; 95%CI, 1.33-3.21; I2 = 56%). Subgroup and sensitivity analyses suggested a significant association between aminoglycoside use and studies limited to patients with clinical weakness (OR, 2.74; 95%CI, 1.83-4.10; I2 = 0%), and not to studies limited to patients with abnormal electrophysiology (OR, 1.78; 95%CI, 0.94-3.39; I2 = 59%), a large sample size (OR, 1.81; 95%CI, 0.97-3.39; I2 = 75%), or low risk of bias (OR, 1.59; 95%CI, 0.97-2.60; I2 = 56%); however, statistical heterogeneity was obvious. There were no significant publication biases found in the review.

Conclusions: The review revealed a significant relationship between aminoglycoside use and ICU-acquired weakness.

Citing Articles

Which factors are associated with acquired weakness in the ICU? An overview of systematic reviews and meta-analyses.

Fuentes-Aspe R, Gutierrez-Arias R, Gonzalez-Seguel F, Marzuca-Nassr G, Torres-Castro R, Najum-Flores J J Intensive Care. 2024; 12(1):33.

PMID: 39232808 PMC: 11375885. DOI: 10.1186/s40560-024-00744-0.

Intensive care unit-acquired weakness: Recent insights.

Chen J, Huang M J Intensive Med. 2024; 4(1):73-80.

PMID: 38263973 PMC: 10800771. DOI: 10.1016/j.jointm.2023.07.002.

A Cross-Sectional Study of the Impact of ICU-Acquired Weakness: Prevalence, Associations, and Severity.

Khalil A, Alamri R, Aljabri G, Shahat E, Almughamsi R, Almeshhen W Cureus. 2024; 15(12):e49852.

PMID: 38174172 PMC: 10762283. DOI: 10.7759/cureus.49852.

Influence of Early Multidisciplinary Collaboration on Prevention of ICU-Acquired Weakness in Critically Ill Patients.

Wang B, He X, Tian S, Feng C, Feng W, Song L Dis Markers. 2022; 2022:3823368.

PMID: 35942131 PMC: 9356837. DOI: 10.1155/2022/3823368.

One-Year Outcomes of Postintensive Care Syndrome in Critically Ill Coronavirus Disease 2019 Patients: A Single Institutional Study.

Banno A, Hifumi T, Takahashi Y, Soh M, Sakaguchi A, Shimano S Crit Care Explor. 2022; 3(12):e0595.

PMID: 34984342 PMC: 8718183. DOI: 10.1097/CCE.0000000000000595.

References

Takahashi Y, Igarashi M . Destination of aminoglycoside antibiotics in the 'post-antibiotic era'. J Antibiot (Tokyo). 2017; . DOI: 10.1038/ja.2017.117. View

Weber-Carstens S, Deja M, Koch S, Spranger J, Bubser F, Wernecke K . Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care. 2010; 14(3):R119. PMC: 2911767. DOI: 10.1186/cc9074. View

Vakulenko S, Mobashery S . Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003; 16(3):430-50. PMC: 164221. DOI: 10.1128/CMR.16.3.430-450.2003. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Wright J, Collier B . The effects of neomycin upon transmitter release and action. J Pharmacol Exp Ther. 1977; 200(3):576-87. View

Fan E, Cheek F, Chlan L, Gosselink R, Hart N, Herridge M . An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med. 2014; 190(12):1437-46. DOI: 10.1164/rccm.201411-2011ST. View

de Jonghe B, Sharshar T, Lefaucheur J, Authier F, Durand-Zaleski I, Boussarsar M . Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002; 288(22):2859-67. DOI: 10.1001/jama.288.22.2859. View

Nanas S, Kritikos K, Angelopoulos E, Siafaka A, Tsikriki S, Poriazi M . Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit. Acta Neurol Scand. 2008; 118(3):175-81. DOI: 10.1111/j.1600-0404.2008.00996.x. View

Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A . Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2014; 190(4):410-20. DOI: 10.1164/rccm.201312-2257OC. View

10.

Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S . Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med. 1998; 23(11):1144-9. DOI: 10.1007/s001340050471. View

11.

de Jonghe B, Bastuji-Garin S, Sharshar T, Outin H, Brochard L . Does ICU-acquired paresis lengthen weaning from mechanical ventilation?. Intensive Care Med. 2004; 30(6):1117-21. DOI: 10.1007/s00134-004-2174-z. View

12.

De Letter M, Schmitz P, Visser L, Verheul F, Schellens R, Op de Coul D . Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2002; 29(12):2281-6. DOI: 10.1097/00003246-200112000-00008. View

13.

Stevens R, Marshall S, Cornblath D, Hoke A, Needham D, de Jonghe B . A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2010; 37(10 Suppl):S299-308. DOI: 10.1097/CCM.0b013e3181b6ef67. View

14.

Barrons R . Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 1997; 17(6):1220-32. View

15.

Parsons T, Obaid A, Salzberg B . Aminoglycoside antibiotics block voltage-dependent calcium channels in intact vertebrate nerve terminals. J Gen Physiol. 1992; 99(4):491-504. PMC: 2219205. DOI: 10.1085/jgp.99.4.491. View

16.

Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia J, Ortiz-Leyba C, Jimenez-Jimenez F . Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001; 27(8):1288-96. DOI: 10.1007/s001340101009. View

17.

Nguyen The L, Huu C . Critical illness polyneuropathy and myopathy in a rural area in Vietnam. J Neurol Sci. 2015; 357(1-2):276-81. DOI: 10.1016/j.jns.2015.08.005. View

18.

Grill M, Maganti R . Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011; 72(3):381-93. PMC: 3175508. DOI: 10.1111/j.1365-2125.2011.03991.x. View

19.

Wieske L, Witteveen E, Verhamme C, Dettling-Ihnenfeldt D, van der Schaaf M, Schultz M . Early prediction of intensive care unit-acquired weakness using easily available parameters: a prospective observational study. PLoS One. 2014; 9(10):e111259. PMC: 4210178. DOI: 10.1371/journal.pone.0111259. View

20.

Yang T, Li Z, Jiang L, Wang Y, Xi X . Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis. Acta Neurol Scand. 2018; 138(2):104-114. DOI: 10.1111/ane.12964. View